Peg-Grafted Liposomes for L-Asparaginase Encapsulation

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Nanomedicine
• Oncology

Background:

• L-asparaginase (ASNase) is a critical therapeutic agent for Acute Lymphoblastic Leukemia (ALL), functioning by depleting L-asparagine essential for leukemia cell survival.
• Current ASNase treatments face challenges including hypersensitivity, immunogenicity, and rapid degradation by plasma proteases, limiting their clinical effectiveness and duration.
• Liposomal encapsulation offers a strategy to shield ASNase from proteolytic enzymes and the immune system, potentially improving its pharmacokinetic profile and therapeutic index.

Purpose of the Study:

• To develop and characterize liposomal formulations of L-asparaginase (ASNase) for enhanced stability and therapeutic potential in Acute Lymphoblastic Leukemia (ALL) treatment.
• To evaluate the impact of different phospholipid compositions, including PEGylated lipids (DSPE-PEG), on the physicochemical properties and enzymatic activity of encapsulated ASNase.
• To assess the in vitro cytotoxic efficacy of the optimized liposomal ASNase formulation against the Molt 4 leukemic cell line.

Main Methods:

• L-asparaginase (ASNase) was encapsulated into liposomes composed of DOPC or DMPC, with varying concentrations of DSPE-PEG.
• Liposome characteristics, including size, polydispersity index (PDI), and morphology, were analyzed using Transmission Electron Microscopy (TEM and cryo-TEM).
• Encapsulation efficiency (%EE) was determined, and enzymatic activity was assessed in vitro against ASNase substrate and the Molt 4 leukemic cell line.

Main Results:

• Liposomal formulations with diameters ranging from 142-202 nm and low PDI (0.069-0.190) were successfully prepared.
• Encapsulation efficiency (%EE) ranged from 10% to 16%, with all formulations retaining ASNase activity, suggesting liposome permeability or surface adsorption.
• The DMPC/DSPE-PEG 10% formulation exhibited the highest activity and a lower IC50 compared to free ASNase against Molt 4 cells, indicating enhanced efficacy.

Conclusions:

• Liposomal encapsulation of ASNase, particularly with DMPC and DSPE-PEG, provides a promising strategy to protect the enzyme from degradation and immunogenicity.
• The developed liposomal formulation demonstrates potential for improved in vivo activity and pharmacokinetics, offering a more stable and effective treatment for ALL.
• Further investigation into these nanostructured drug delivery systems could lead to advanced therapeutic options for hematological malignancies.